Bisoprolol market seen rising to $3.26 billion by 2030
The Business Research Company says the global bisoprolol market will grow from $2.17 billion in 2025 to $2.35 billion in 2026, then reach $3.26 billion by 2030. The forecast points to stronger demand for cardiovascular treatment as hypertension and other heart conditions rise worldwide.
Why it matters: - Bisoprolol is a widely used beta-blocker for hypertension, heart failure and angina, so demand tracks broader cardiovascular disease trends. - The market outlook points to sustained growth in a drug category tied to long-term blood pressure management and chronic care. - The report suggests more opportunity for generic drugs, pharmacy distribution and outpatient cardiac care as cardiovascular cases rise.
What happened: - The Business Research Company released its Bisoprolol Market Analysis Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the bisoprolol market will grow from $2.17 billion in 2025 to $2.35 billion in 2026. - The forecast calls for the market to reach $3.26 billion by 2030. - North America held the largest bisoprolol market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the bisoprolol market report. - View the full bisoprolol market report.
The details: - The report projects an 8.5% compound annual growth rate from 2025 to 2026. - The same 8.5% CAGR is projected through 2030. - Growth drivers include the high prevalence of hypertension, proven effectiveness of beta-blockers, an aging global population, enhanced hospital-based cardiac care and widespread prescribing by physicians. - Longer-range growth is tied to a rising cardiovascular disease burden, broader access to generic medicines, advances in outpatient cardiac care, expanding pharmacy networks and better patient adherence. - The report identifies higher rates of cardiovascular conditions, more chronic use of beta-blockers, greater acceptance of generic cardiovascular drugs, expansion of retail and hospital pharmacies and a stronger focus on long-term blood pressure control as key trends. - Bisoprolol works by blocking adrenaline’s effect on the heart, which lowers heart rate and blood pressure and reduces cardiac workload. - The report says hypertension prevalence among adults in Singapore rose to 36.1% in 2023 from 33.0% the year before, citing the Singapore Ministry of Health in February 2024. - The report says that increase highlights growing demand for hypertension treatment.
Between the lines: - The forecast suggests bisoprolol is benefiting from a durable, treatment-led market rather than a short-term demand spike. - North America’s lead indicates established access and prescribing patterns, while other regions may gain share as cardiovascular infrastructure expands. - The emphasis on generics and pharmacy channels points to a market where distribution and affordability matter as much as clinical demand.
What's next: - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated technology and trend analysis. - Further demand will likely depend on hypertension incidence, adoption of chronic beta-blocker therapy and the spread of cardiovascular care settings outside hospitals. - The report points to continued expansion through 2030 if current treatment and demographic trends hold.
The bottom line: - Bisoprolol is on a steady growth path, with rising hypertension and wider cardiovascular care access supporting a market expected to top $3.26 billion by 2030.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia News Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.